March 22, 2017 (Rye Brook, NY) – As the world’s leading non-profit dedicated to fighting blood cancers, The Leukemia & Lymphoma Society (LLS) has play…
News Release
There are widely recognized but unexplained sex differences in cancer incidence and outcomes, including in blastic plasmacytoid dendritic cell neoplas…
MLL1/KMT2A rearranged leukemias are the most common blood cancer occurring in children characterized by dismal prognosis. Given the importance of fusi…
Blinatumomab has received full approval from the FDA after long-term data confirmed its safety and efficacy.
The Food and Drug Administration (FDA) recently approved a combination of the targeted therapy ivosidenib (Tibsovo) and the chemotherapy azacitidine f…
The Leukemia & Lymphoma Society (LLS) Announces National Winners of Evolutionary ‘Visionaries of the Year’ Campaign; Funds Raised Will Help LLS Improv…
News Release
SAN DIEGO, December 8, 2023 – Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of pre…
News Release
Dr. Abdel-Wahab of Memorial Sloan Kettering Cancer Center focuses on an area of research called epigenetics – chemical modifications that regulate (sw…
Niclosamide is an FDA approved anti-parasitic drug that is well tolerated and acts synergistically with chemotherapy to kill AML cells. We will conduc…
In a new, independent analysis of chronic disease organizations by Cause Reports, The Leukemia & Lymphoma Society (LLS) received the highest score and…
News Release
More than 6,000 school-age children are affected by leukemia and lymphoma each year. These blood cancers account for about 40 percent of all childhood…
The Leukemia & Lymphoma Society is proud to announce that because of its strong financial health and ongoing accountability and transparency, LLS has …
News Release
Read this heartfelt message from E. Anders Kolb, M.D.as he takes on the role of CEO & President of The Leukemia & Lymphoma Society.
This fact sheet provides information about diagnosis, treatment, expected outcomes and available support resources for chronic neutrophilic leukemia (CNL).
This fact sheet provides information about hairy cell leukemia (HCL), including information about treatment, clinical trials, and support resources.
October 10, 2022 – Starting today through November 14, 2022, Burlington Stores is encouraging customers to donate at checkout in their more than 870 s…
The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…
News Release
Asciminib provides another option to help CML patients live longer, healthier lives Rye Brook, N.Y., December 6, 2024 – The U.S. Food and Drug Adminis…
News Release
no-float 100 Rye Brook, N.Y., July 25, 2023 – The U.S. Food and Dr…
News Release
January 30, 2025 – This week, LLS has heard great concern from patients, caregivers, volunteers, healthcare professionals, researchers, community orga…
News Release
Topics CoveredWe invite you to learn more about:Current and emerging treatments for ALLSide-effect managementBuilding strong communication with your h…
Education Resources
Subaru Celebrates Ten Years Partnering with The Leukemia & Lymphoma Society To Support Nearly 500,000 Cancer Patients and Families NationwideAutomaker…
News Release
Click Here to ParticipateRecorded on: February 25, 2025Estimated Time to Complete: 2.5 hours2.5 CE Credits/Contact hours for nurses and social workers…
Education Resources
Click Here to ParticipateRecorded on: February 4, 2025Estimated Time to Complete: 1.75 hours1.75 CE Credits/Contact hours for nurses and social worker…
Education Resources
The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.